VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 15, 2008) - Pacgen Biopharmaceuticals Corporation ("Pacgen") (TSX VENTURE: PGA) announced today that it has completed the recruitment of patients in its Phase IIb dose-ranging clinical trial for PAC-113, a novel treatment for oral Candidiasis infection. The Company is on track to report final results from this study in June 2008.
